Promising PSMA-Targeted Therapy Delays Prostate...

By HEOR Staff Writer

October 20, 2025

Novartis recently announced pivotal data from the Phase III PSMAddition trial. It demonstrates that PSMA-targeted therapy with Pluvictoâ„¢ (lutetium-177 vipivotide tetraxetan) combined with standard of care (androgen receptor pathway inhibitor plus ...
Cabotegravir HIV Prevention: First Injectable PrEP Recommended for High-Risk ...
Social Media Policy Action: Protecting Youth from Cognitive Risks
Johnson & Johnson Advances Solid Tumor Research at ESMO 2025 with Promis...
Colorectal Cancer Markers: Discovering Region-Specific Drivers for Precision ...
Tukysa Breast Cancer Therapy Boosts Progression-Free Survival in Advanced Cases
Datroway TNBC Therapy: Transforming First-Line Treatment for Metastatic Tripl...
Evolving Burden of Obesity in the US: Key Insights on Obesity Prevention Stra...
Simponi Pediatric Approval: FDA Grants First Pediatric Indication for Ulcerat...
Lurbinectedin SCLC Therapy: FDA Approval and Its Economic Implications
Enhertu Breast Cancer Treatment: Major Advances in Invasive Disease-Free Surv...
Transforming Healthcare with the Gene Therapy Access Model
Sanofi Insulin Savings: Your Comprehensive Guide for 2025